Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402

PURPOSE: A randomized phase II trial of two novel treatment strategies in the first-line management of advanced non–small-cell lung cancer patients with performance status (PS) 2. PATIENTS AND METHODS: Patients were assigned to docetaxel 30 mg/m(2) on days 1, 8, and 15 every 28 days in combination w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lilenbaum, Rogerio, Wang, Xiaofei, Gu, Lin, Kirshner, Jeffrey, Lerro, Keith, Vokes, Everett
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754901/
https://ncbi.nlm.nih.gov/pubmed/19704058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.7066
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados